Journal of Clinical Hepatology
This article retrospectively analyzes the clinical characteristics and influencing factors of 6 Chinese liver cancer staging (CNLC) stage III hepatocellular carcinoma (HCC) patients who achieved continuous 5-year complete remission (CR) after receiving local treatment combined with systemic treatment. The study found that all patients received TACE treatment, followed by targeted drugs (such as sorafenib, lenvatinib), and some combined immunotherapy or 125I particle implantation. The patency rate of the portal vein in patients with portal vein thrombus was significantly improved after combined particle implantation. The patients had good baseline liver function (MELD score ≤9, Child-Pugh A/B grade), good tolerance to treatment, indicating that good liver function is an important basis for achieving long-term CR. In addition, the early significant decrease in AFP is related to CR and may become a biomarker for predicting efficacy. The innovation lies in the first systematic summary of the multi-modal treatment strategies and clinical characteristics for achieving long-term CR in advanced HCC, providing empirical evidence for optimizing individualized treatment for advanced HCC.
This study explores the clinical characteristics and influencing factors of advanced hepatocellular carcinoma (HCC) patients who achieve continuous 5-year complete remission (CR) after combined local and systemic treatment, which has important clinical guiding significance. The study shows that all patients received TACE combined with targeted or immunotherapy, and some combined 125I particle implantation, indicating that multi-modal comprehensive treatment is the key to achieving long-term CR. Good baseline liver function, early rapid decrease in alpha-fetoprotein (AFP), and effective control of portal vein thrombus are closely related to efficacy. In particular, 4 patients with portal vein trunk involvement achieved vascular recanalization after combined treatment, significantly improving the prognosis, reflecting the value of local intensive treatment in complex cases. In addition, the median follow-up of 63 months confirmed that the treatment strategy has good long-term safety and controllable severe adverse reactions. This study provides real-world evidence for optimizing individualized combined treatment plans for advanced HCC, suggesting that through multidisciplinary collaboration, it is possible to achieve long-term survival or even clinical cure in some advanced patients, which is worthy of further multi-center research verification.
Objective: To investigate the clinical features of patients with China Liver Cancer Staging (CNLC) stage Ⅲ hepatocellular carcinoma…
